AI-Validated Brain Targeted mRNA Lipid Nanoparticles with Neuronal Tropism

Authors:

Top Cited Papers
Open Access
Abstract
Targeting therapeutic nanoparticles to the brain poses a challenge due to the restrictive nature of the blood-brain barrier (BBB). Here we report the development of mRNA-loaded lipid nanoparticles (LNPs) functionalized with BBB-interacting small molecules, thereby enhancing brain delivery and gene expression. Screening brain-targeted mRNA-LNPs in central nervous system (CNS) in vitro models and through intravenous administration in mice demonstrated that acetylcholine-conjugated LNPs achieved superior brain tropism and gene expression, outperforming LNP modifications with nicotine, glucose, memantine, cocaine, tryptophan, and other small molecules. An artificial intelligence (AI)-based model designed to predict the BBB permeability of small-molecule ligands showed strong alignment with our experimental results, providing in vivo validation of its predictive capacity. Cell-specific biodistribution analysis in Cre-reporter Ai9 mice showed that acetylcholine-functionalized LNPs preferentially transfected neurons and astrocytes following either intravenous or intracerebral administration. Mechanistic studies suggest that acetylcholine-LNP uptake is mediated by the functional engagement of acetylcholine receptors (AchRs) followed by endocytosis, which synergistically enhances intracellular mRNA delivery. Moreover, acetylcholine-LNPs successfully crossed a human BBB-on-a-chip model, enabling transgene expression in human iPSC-derived neurons. Their effective penetration and transfection in human brain organoids further support their potential activity in human-based systems. These findings establish a predictive and modular framework for engineering CNS-targeted LNPs, advancing precision gene delivery for brain disorders.
Funding Information
  • European Research Council (101040128, 101089009, 101170349, 851765)
  • Israel Science Foundation (1384/21, 1385/21, 1881/21, 1934/23, 2141/20)
  • H2020 Marie Sklodowska-Curie Actions (101007804, 101086329)
  • Azrieli Foundation
  • Teva Pharmaceutical Industries
  • Russell Berrie Nanotechnology Institute, Technion-Israel Institute of Technology
  • Baroness Ariane de Rothschild Women Doctoral Program from the Edmond de Rothschild Foundation
  • BrightFocus grant (A2022029S)
  • NIH Grant (1R21AG074846-01A1)
  • Mallat Family Foundation
  • PRISM - 2BCured
  • Rappaport - Technion Integrated Cancer Center
  • Lorry I. Lokey Interdisciplinary Center for Life Sciences & Engineering (LS&E)
  • Ministry of Innovation, Science and Technology, Israel (1001576154, 317351, 8-2175)
  • Diane Sherman Prize for Medical Innovation for a Better World
  • Volkswagen Stiftung: Forschungskooperation Niedersachsen-Israel
  • The Aufzien Family Center for the Prevention and Treatment of Parkinson?s Disease at Tel Aviv University
  • Michael J. Fox Foundation (MJFF-022407)
  • VATAT Scholarship Program
  • Ben Barres Early Career award from the Chan Zuckerberg Initiative (CZI)
  • Unger Family Fund
  • Biomedical Core Facility (BCF)
  • Innovation Authority ?BioChip?
  • Levinson Family Recruitment Fund (ATS 11647)
  • The Louis Family Fund for Targeted Drug Delivery & Personalized Medicine Technologies (ATS 11948)

This publication has 100 references indexed in Scilit: